Tag: Neupro

Rotigotine (brand name Neupro), a medication for Parkinson's disease and Restless Legs Syndrome, is classified as a non-ergoline dopamine agonist that utilizes a unique transdermal patch for continuous delivery. This provides a stable medication level, mimicking physiological dopamine stimulation and avoiding the peaks and troughs associated with oral administration.

Clinical studies have demonstrated sustained efficacy and tolerability of the rotigotine patch (brand name Neupro) for up to 5 to 6 years in treating chronic neurological conditions like Parkinson's disease (PD) and restless legs syndrome (RLS). As a viable option for long-term therapy, understanding the duration of use and associated considerations is essential for patients managing these conditions.

The prevalence of Restless Legs Syndrome (RLS) in patients with Parkinson's disease (PD) is estimated to be around 20%, significantly higher than in the general population [1.8.6]. For both conditions, dopamine agonists are a key treatment. So, what is the difference between pramipexole and rotigotine, two common drugs in this class? [1.5.1]

According to the European Medicines Agency, the Neupro® (rotigotine transdermal system) patch is used to manage the symptoms of both Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome in adults. This once-daily application provides a continuous, steady delivery of the medication over a 24-hour period, helping to control movement and discomfort.